Dr. Reddy’s Laboratories to Engage in Investor Conferences in June 2025

Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.

Dr. Reddy’s Laboratories announced its participation in upcoming investor conferences scheduled between June 10 and June 13, 2025. The company will engage with institutional investors and groups in Mumbai and Singapore, organized by Nomura, Investec, and Bank of America. These meetings are part of the company’s efforts to maintain transparency and communication with its stakeholders, potentially impacting investor relations and market perceptions.

The most recent analyst rating on (RDY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical company based in Hyderabad, India. The company is engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products, including generic medicines, active pharmaceutical ingredients, and over-the-counter drugs. Dr. Reddy’s focuses on providing affordable and innovative medicines in various therapeutic areas to markets across the globe.

Average Trading Volume: 2,055,866

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.13B

For an in-depth examination of RDY stock, go to TipRanks’ Stock Analysis page.